NCM
PBYI icon

Next Capital Management’s Puma Biotechnology PBYI Stock Holding History

Next Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-196
Closed -$2K – 643
2019
Q2 		$2K Buy
+196
New +$4.51K ﹤0.01% 768

Other funds holding PBYI

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Next Capital Management's PBYI Position: Q3 2019 in Review

Next Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2019, closing a stake of 196 shares — an estimated $2K sold.

Next Capital Management first reported a position in PBYI in Q2 2019 and held it in 1 quarter. The position peaked at $2K in Q2 2019. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

  • Next Capital Management reported no remaining Puma Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Next Capital Management sold 196 Puma Biotechnology shares in Q3 2019, an estimated $2K.
  • Next Capital Management first reported a position in Puma Biotechnology in Q2 2019 and held it in 1 quarter.
  • Next Capital Management's Puma Biotechnology position peaked at $2K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Next Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.